Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alberto L. Machado"'
Autor:
Gilberto K. Furuzawa, Cleber P. Camacho, M Cecília Martins-Costa, Magnus R. Dias-da-Silva, Lucas Leite Cunha, Renata P. Dotto, João Roberto Maciel Martins, Susan C. Lindsey, Rui M. B. Maciel, Márcio M Martins, M Sharmila A Sousa, Teresa S. Kasamatsu, Alberto L. Machado, Ilda S. Kunii
Publikováno v:
Endocrine-Related Cancer. 23:909-920
Germline mutations in codon 918 of exon 16 of theRETgene (M918T) are classically associated with multiple endocrine neoplasia type 2B (MEN 2B) with highly aggressive medullary thyroid cancer (MTC), pheochromocytoma and a unique phenotype. The objecti
Autor:
Rosa Paula M. Biscolla, Maria Conceição Mamone, Susan C. Lindsey, Rui M. B. Maciel, R. M. Tuttle, Magnus R. Dias-da-Silva, Fabio Brodskyn, Cleber P. Camacho, Alberto L. Machado, Fausto Germano-Neto, Flávia O. F. Valente, Ji H. Yang
Publikováno v:
Clinical Endocrinology. 83:938-942
Objective Staging systems applied to medullary thyroid cancer (MTC) rely on initial clinical and pathological features and do not consider the response to treatment. To determine whether MTC staging can be improved by incorporating the first postoper
Autor:
Magnus R. Dias da Silva, Cleber P. Camacho, Rui M. B. Maciel, Susan C. Lindsey, João Roberto Maciel Martins, Rosa Paula M. Biscolla, José Gilberto H. Vieira, Teresa S. Kasamatsu, Alberto L. Machado
Publikováno v:
European Thyroid Journal. 3:117-124
Background: Serum calcitonin (sCT) is a useful biomarker for medullary thyroid cancer (MTC). Consensus has not been reached concerning sCT measurements in the evaluation of nodular thyroid disease (NTD). Objective and Methods: We developed a new immu
Autor:
Magnus R. Dias-da-Silva, Susan C. Lindsey, Teresa S. Kasamatsu, Alberto L. Machado, Janete M. Cerutti, Camila P. Salim, Rui M. B. Maciel, Flávia O. F. Valente, Cleber P. Camacho, Ana O. Hoff, Priscila S. Signorini, Rosana Delcelo, Maria Inez C. Franca
Publikováno v:
Clinical Endocrinology. 80:235-245
SummaryObjective Reviewing the clinical outcomes of a large kindred with a RET p.Gly533Cys mutation, 10 years after the first description of this kindred, has provided an important set of clinical data for healthcare decision-making. Design and Patie